Filing Flows › Kestra Medical Technologies (KMTS) › Q2 FY26
Kestra Medical Technologies (KMTS) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Dec 11, 2025
Kestra Medical Technologies (KMTS) reported revenue of $22.6M for the second quarter fiscal 2026 (Q2 FY26), +53% from a year earlier and +16% from the quarter before. Operating margin was -140.7%, net loss $32.8M (145.3% of revenue).
Kestra Medical Technologies, Q2 FY26: revenue $22.6M (+53% year over year), operating margin -140.7%, net loss $32.8M, operating cash flow −$18.3M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.6M | +16% | +53% |
| Operating profit | −$31.8M | — | — |
| Net earnings | −$32.8M | — | — |
| Operating cash flow | −$18.3M | — | — |
What changed
Revenue was $22.6M in Q2 FY26, up 53% year over year and up 16% from the previous quarter.
Gross margin was 50.6%, up 11.0 points from a year earlier. Operating costs exceeded revenue by $31.8M, an operating margin of -140.7%. Operating expenses grew 73% against revenue growth of 53%. The fastest-growing cost line was SG&A (+79%). The quarter ended with a net loss of $32.8M, wider than the previous quarter's $25.8M loss.
Operating cash flow was −$18.3M. Non-cash charges added back $2.4M of depreciation and $8.7M of share-based compensation. Working capital and other items added $3.4M. Capital expenditures of $7.3M exceeded it, leaving free cash flow of −$25.6M.
Questions
What was Kestra Medical Technologies' revenue in the second quarter fiscal 2026?
Kestra Medical Technologies (KMTS) reported revenue of $22.6M for the second quarter fiscal 2026 (Q2 FY26), +53% from a year earlier and +16% from the quarter before.
Was Kestra Medical Technologies profitable in the second quarter fiscal 2026?
Operating loss was $31.8M (-140.7% of revenue) and net loss $32.8M.